옵션 체인은 다양한 행사가격과 만기일에 대한 Boxlight의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Boxlight에 대한 시장 심리를 평가합니다..

Boxlight (NASDAQ:BOXL) 주식, 옵션 체인

Boxlight

Boxlight Corp is a technology company that develops, sells and services interactive solutions predominantly for the education market, but also for the corporates and government sectors. The company currently designs, produces and distributes interactive technologies including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras and other peripherals for the education market and non-interactive solutions including flat panels, LED video walls and digital signage. The company also distributes science, technology, engineering and math (or STEM) products, including 3D printing and robotics solutions, and a portable science lab.

Boxlight Corporation - Class A Common Stock

Boxlight Corp

BofA Securities analyst Craig Siegenthaler forecasts the major earnings beats for brokers this earnings season, <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">steered by accelerating retail engagement.</a>
Siegenthaler also sees broad-based beats for traditional firms, supported by strong markets, foreign exchange, and higher management fees and non-operating income.
Here are a few of the most considerable companies, along with the analyst&#8217;s insights on them:
Virtu Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>): The analyst reiterated a Buy rating on the stock,<a target="_blank" href="https://www.benzinga.com/quote/VIRT/analyst-ratings" rel="noreferrer noopener"> lowering the price forecast to $51 from $52.</a>
The analyst revised their EPS estimates for the fourth quarter of 2024, FY25, and FY26 to $0.94, $3.58, and $3.71, respectively, from previous estimates of $0.88, $3.65, and $3.78.
The increase in the fourth quarter estimate is attributed to a surge in retail activity driven by the U.S. election and strong market returns since August, with several retail brokerages reaching multi-year volume records. However, the revisions were offset by a reduction in the company&#8217;s market share and capture, as intra-quarter disclosures indicated a significant drop in market share sequentially.
Additionally, the volatility environment is expected to reduce revenue per share. The analyst writes that once retail activity slows down, market share and monetization challenges could become a bigger issue for the stock.
Also Read:<a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/01/42881085/is-labor-market-cooling-or-raising-fed-concerns-what-to-watch-in-fridays-jobs-report" rel="noreferrer noopener"> Is Labor Market Cooling Or Raising Fed Concerns? What To Watch In Friday&#8217;s Jobs Report</a>
Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): The analyst reiterated the Buy rating on the stock, <a target="_blank" href="https://www.benzinga.com/quote/HOOD/analyst-ratings" rel="noreferrer noopener">raising the price forecast to $55 from $53. </a>Siegenthaler notes that both Robinhood and Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) have benefited from the recent crypto bull market, with the total cryptocurrency market cap surpassing its 2021 high due to election results, hopes for a transparent regulatory framework, and a more dovish environment.
While acknowledging the high valuations in the space, the analyst remains bullish, citing accelerating earnings potential driven by factors such as a bullish market beta, increases in nominal client cash balances, higher demand for borrowing and capital markets activity, and higher-for-longer rates that limit NIM compression.
The analyst raised their HOOD adjusted EPS estimates for 4Q24, 2026, and 2027 to $0.42, $1.41, and $1.82, respectively, from $0.22, $1.35, and $1.75, due to higher client activity, especially in crypto volumes.
BlackRock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>): The analyst reiterated the Buy rating on the stock,<a target="_blank" href="https://www.benzinga.com/quote/BLK/analyst-ratings" rel="noreferrer noopener"> raising the price forecast to $1,237 from $1,227.</a>
The analyst estimates BlackRock&#8217;s long-term organic growth to be 5% in 2024, up from 3% in 2023.
Siegenthaler sees a re-acceleration in 2025, primarily driven by BlackRock&#8217;s leading bond ETF business, anticipating passive investments will capture 60-70% of the fixed income rebalancing wave.
Additionally, the analyst sees potential upside to the 4Q24 consensus EPS due to positive beta from management fees and increased performance fees, although from lower-quality items.
The analyst raised their 4Q24/2025/2026 EPS estimates to $11.76/$47.70/$54.18, up from $11.32/$47.27/$53.73, mainly due to positive market conditions (beta) and foreign exchange (FX) factors.
Price Action: VIRT shares are trading higher by 1.64% to $36.77 at last check Wednesday. HOOD shares are trading lower by 0.09% to $40.53, and BLK shares are trading higher by 0.23% to $983.03.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42878896/dollar-jumps-to-14-month-highs-30-year-yields-near-danger-zone-as-trump-mulls-national-economic-emergency-to-set-tariffs" target="_blank" rel="noreferrer noopener">Dollar Hits 14-Month High, 30-Year Yields Near Critical Threshold As Trump Reportedly Mulls Economic Emergency Tariffs</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

News

Price Target

Reiteration

Markets

Analyst Ratings

Trading Ideas

General

COIN

HOOD

VIRT

Analyst Predicts Strong Earnings For Brokers Amid Solid Retail Engagement: Virtu Financial, Robinhood, And BlackRock Under The Spotlight

WIIM

Shares of California utility companies are trading lower amid wildfires in California.

JP Morgan analyst Jeffrey Zekauskas maintains RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Neutral and lowers the price target from $126 to $124.

JP Morgan Maintains Neutral on RPM Intl, Lowers Price Target to $124

JP Morgan analyst Matthew Boss maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Overweight and raises the price target from $425 to $428.

LULU

JP Morgan Maintains Overweight on Lululemon Athletica, Raises Price Target to $428

JP Morgan analyst Matthew Boss maintains Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) with a Overweight and lowers the price target from $21 to $20.

JP Morgan Maintains Overweight on Macy's, Lowers Price Target to $20

JP Morgan analyst Matthew Boss maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Neutral and raises the price target from $46 to $54.

URBN

JP Morgan Maintains Neutral on Urban Outfitters, Raises Price Target to $54

JP Morgan analyst Matthew Boss maintains Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) with a Underweight and lowers the price target from $110 to $107.

FIVE

JP Morgan Maintains Underweight on Five Below, Lowers Price Target to $107

American Intl Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) short percent of float has risen 4.6% since its last report. The company recently reported that it has 10.38 million shares sold short, which is 1.82% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>American Intl Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736365523_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for American Intl Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing American Intl Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, American Intl Gr's peer group average for short interest as a percentage of float is 1.52%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into American Intl Gr's Recent Short Interest

Candel Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NYSE">CADL</a>) short percent of float has risen 36.6% since its last report. The company recently reported that it has 4.57 million shares sold short, which is 13.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Candel Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736365517_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Candel Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Candel Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Candel Therapeutics's peer group average for short interest as a percentage of float is 13.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CADL

How Is The Market Feeling About Candel Therapeutics?

JP Morgan analyst Matthew Boss maintains Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) with a Overweight and raises the price target from $181 to $188.

BOOT

JP Morgan Maintains Overweight on Boot Barn Holdings, Raises Price Target to $188

SharkNinja's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) short percent of float has fallen 15.53% since its last report. The company recently reported that it has 2.70 million shares sold short, which is 4.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>SharkNinja Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736365512_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SharkNinja has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing SharkNinja's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SharkNinja's peer group average for short interest as a percentage of float is 7.10%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into SharkNinja's Recent Short Interest

JP Morgan analyst Matthew Boss maintains American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) with a Neutral and lowers the price target from $23 to $20.

JP Morgan Maintains Neutral on American Eagle Outfitters, Lowers Price Target to $20

Jefferies analyst Julien Dumoulin-Smith initiates coverage on MDU Resources Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDU#NYSE">MDU</a>) with a Hold rating and announces Price Target of $18.

Initiation

Jefferies Initiates Coverage On MDU Resources Gr with Hold Rating, Announces Price Target of $18

Jefferies analyst James Heaney maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $400 to $425.

Jefferies Maintains Buy on AppLovin, Raises Price Target to $425

Guggenheim analyst Michael Schmidt maintains SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Buy and lowers the price target from $80 to $78.

SWTX

Guggenheim Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $78

Unease about inflation's persistence and potential policy shifts under a new White House administration dominated the Federal Reserve's December meeting, leaving policymakers divided on the pace <a href="https://www.benzinga.com/topic/interest-rates">of future rate adjustments.</a>
Minutes from the Dec. 18 Federal Reserve meeting that were released Wednesday paint a cautious picture of the central bank's outlook on inflation and interest rates.
The Fed cut rates by 25 basis points at the meeting, bringing the federal funds rate to 4.25%-4.5%, and emphasized the path ahead would require a delicate balance between curbing inflation and supporting economic growth.
&#8220;Participants indicated that the Committee was at or near the point at which it would be appropriate to slow the pace of policy easing,&#8221; according to the Fed&#8217;s December minutes. 
The minutes also highlight rising uncertainty about inflation and the broader economy, particularly as fiscal and trade policies face potential shifts under the incoming Donald Trump administration.
<h3 class="wp-block-heading">Why Is Inflation Anxiety Rising Again?</h3>
While inflation has shown signs of moderating, "recent higher-than-expected readings on inflation" suggest it could take longer to return to the 2% target, the minutes say.
Cleveland Fed President Beth Hammack was the sole dissenting vote against an interest rate cut in December, favoring an unchanged rate target of 4.5%-4.75%.
Hammack indicated "uneven progress" toward the Fed's inflation target, alongside robust labor market and economic conditions, as key reasons not to cut interest rates further.
The prospect of significant policy shifts under Trump has left Fed officials navigating uncharted waters. Key campaign promises, such as reworking trade agreements, imposing tariffs and enacting tax reform, could have sweeping impacts on the U.S. economy, particularly on inflation.
"A number of participants indicated they had incorporated placeholder assumptions regarding potential trade and immigration policy changes into their projections," the minutes state, highlighting the Fed's uncertainty about the fiscal environment ahead.
"The effects of potential changes in trade and immigration policy suggested that the process [of reaching the 2% inflation target] could take longer than previously anticipated," the minutes say.
<h3 class="wp-block-heading">Inflation, Economic Projections Adjusted</h3>
The Fed updated its economic projections at the December meeting, and they showed a slower pace of cuts through 2025.
The central bank now projects two 25-basis-point rate reductions next year, down from the four forecasted in September. By the end of 2025, the federal funds rate is expected to hover around 3.9%, with a further decline to 3.4% in 2026.
Notably, the Fed raised its inflation forecasts. Headline Personal Consumption Expenditure inflation for 2025 is now expected to reach 2.5% compared to a prior estimate of 2.1%. Core PCE inflation, which excludes volatile food and energy prices, is projected at 2.5%, up from 2.2%.
Market Reactions
Markets showed muted responses to the Fed minutes, suggesting the hawkish tone from the December meeting had already been priced in by investors.
The U.S. dollar index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – held steady at the 109 level, maintaining its 0.4% intraday gain.
Equities experienced a modest relief rally, with the S&amp;P 500, tracked by SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), reversing earlier losses to trade marginally higher for the session.
Treasury yields were largely unchanged. The 10-year yield hovered at 4.69%, while the 30-year yield remained stable at 4.93%, signaling little movement in bond markets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42881085/is-labor-market-cooling-or-raising-fed-concerns-what-to-watch-in-fridays-jobs-report">Is Labor Market Cooling Or Raising Fed Concerns? What To Watch In Friday&#8217;s Jobs Report</a></li>
</ul>
Photo created using artificial intelligence via Midjourney.

Currency ETFs

Econ #s

Economics

Federal Reserve

ETFs

PowerShares DB US Dollar Index Bullish Fund

Fed Minutes Reveal Inflation Jitters, Policymakers Signal Slower Interest Rate Easing Path Ahead

Guggenheim analyst Michael Morris maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Buy and lowers the price target from $44 to $40.

Guggenheim Maintains Buy on Warner Music Gr, Lowers Price Target to $40

On Tuesday, Alger launched the Alger Russell Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVN#NYSE">INVN</a>), another addition to its lineup of funds aiming to cash in on <a href="https://www.benzinga.com/topic/etf">transformative market opportunities. </a>
The <a href="https://www.prnewswire.com/news-releases/alger-and-ftse-russell-launch-the-alger-russell-innovation-etf-ticker-invn-to-capture-the-next-wave-of-market-disruptors-302342157.html">ETF </a>comes with an expense ratio of 0.55% and mirrors the Alger Russell Innovation Index, which focuses on innovative underdogs with high potential. At least 80% of the fund&#8217;s total assets are invested in securities of the Alger Russell Innovation Index, according to the fund&#8217;s prospectus.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42878368/xrp-etf-very-soon-likely-next-after-bitcoin-and-ethereum-ripple-president-says">XRP ETF &#8216;Very Soon,&#8217; Likely Next After Bitcoin And Ethereum, Ripple President Says</a>
BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), Teradata Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>), and Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) are among the top holdings, accounting for 2.11%, 2.01%, and 2.03% as of Jan. 7. The fund&#8217;s portfolio consists of about 50 holdings.
The index uses a quantitative methodology to identify innovation-driven equities, shortlists them based on lower cash flow margins and then ranks them based on research and development expenditures. The top 50 companies on this ranking are then selected, with each stock constituting around 2% of the portfolio.
Brad Neuman, CFA, Alger's Director of Market Strategy, thinks that this approach could bring innovation &#8220;out of the shadow of financial statements&#8221; and into accessible investment instruments.
The launch of INVN makes it the sixth Alger ETF available on U.S. markets. Among its other offerings, the Alger Mid Cap 40 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRTY#NYSE">FRTY</a>) stands out with over $70 million in assets under management.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies</a></li>
</ul>
Photo: Shutterstock

New ETFs

BMRN

FRTY

INVN

Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators

Investors with a lot of money to spend have taken a bullish stance on CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CVS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 17 uncommon options trades for CVS Health.
This isn't normal.
The overall sentiment of these big-money traders is split between 52% bullish and 47%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $853,576, and 10 are calls, for a total amount of $1,325,759.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $45.0 to $65.0 for CVS Health over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in CVS Health's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to CVS Health's substantial trades, within a strike price spectrum from $45.0 to $65.0 over the preceding 30 days.
<h3>CVS Health Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736364670_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$1.68</td>
<td>$1.61</td>
<td>$1.62</td>
<td>$55.00</td>
<td>$567.0K</td>
<td>2.4K</td>
<td>3.6K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$9.7</td>
<td>$9.35</td>
<td>$9.35</td>
<td>$45.00</td>
<td>$365.6K</td>
<td>2.2K</td>
<td>391</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$10.05</td>
<td>$10.0</td>
<td>$10.05</td>
<td>$52.50</td>
<td>$223.1K</td>
<td>36</td>
<td>224</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.6</td>
<td>$4.3</td>
<td>$4.6</td>
<td>$52.50</td>
<td>$161.9K</td>
<td>4.8K</td>
<td>674</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$9.4</td>
<td>$9.15</td>
<td>$9.15</td>
<td>$45.00</td>
<td>$154.6K</td>
<td>2.2K</td>
<td>730</td>
</tr>
</tbody>
</table>

<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
In light of the recent options history for CVS Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>CVS Health's Current Market Status</h3>
<ul>
<li>With a trading volume of 7,320,414, the price of CVS is up by 0.02%, reaching $45.79.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 35 days from now.</li>
</ul>
<h3>What Analysts Are Saying About CVS Health</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $60.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on CVS Health, maintaining a target price of $60. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CVS Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Market Whales and Their Recent Bets on CVS Options

Guggenheim analyst Joseph Osha initiates coverage on MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Buy rating and announces Price Target of $195.

Guggenheim Initiates Coverage On MasTec with Buy Rating, Announces Price Target of $195

Boxlight Corporation (BOXL) Q2 2024 Earnings Call Transcript

Warning: BOXL is at high risk of performing badly

Boxlight Q3 2024 Earnings Preview

Here are the major earnings after the close today

Reports Q3 revenue $36.3M, consensus $41.06M. "We continue to position our organization for future growth through the alignment of our brand strate...

Boxlight reports Q3 EPS (34c), consensus (16c)

Alliance Global Partners downgraded Boxlight (BOXL) to Neutral from Buy. The company posted lower-than-expected revenue in Q3, and with the quarter...

Boxlight downgraded to Neutral from Buy at Alliance Global Partners

Boxlight Corporation (BOXL) Q3 2024 Earnings Call Transcript

Analyst Scott Buck of H.C. Wainwright maintained a Buy rating on Boxlight (BOXL – Research Report), with a price target of $1.00. Scott Buck has gi...

Strategic Restructuring and Long-term Growth Potential for Boxlight Corporation

Maxim Group analyst Jack Vander Aarde has reiterated their bullish stance on BOXL stock, giving a Buy rating yesterday. Jack Vander Aarde's rating ...

Comments

Boxlight

Boxlight (BOXL) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌